The Advertising Standards Authority has banned a billboard advertisement for a £49 facial serum after determining that claims it could make users look up to five years younger were misleading and unsubstantiated. The poster for Eucerin Hyaluron-Filler Epigenetic Serum, which appeared at Balham tube station in London, claimed the product was “clinically proven” founded on a study of 160 people. However, the watchdog identified significant flaws in the research methodology, including the absence of a control group and dependence on subjective self-reporting from participants. The grievance was lodged in November 2025, prompting the ASA enquiry that ultimately deemed the advertisement misleading and banned it from appearing in its current form.
The Banned Campaign and Its Disputed Claims
The Eucerin marketing campaign relied heavily on a four-week study featuring 160 participants who were merely requested to self-report how much more youthful they believed they appeared after using the serum. This research approach prompted immediate concerns for the ASA, which highlighted multiple significant weaknesses in the study design. Particularly important, the study lacked a control group—a fundamental requirement in scientific research that would have allowed researchers to compare results against a reference point. The lack of such comparisons meant there was no way to establish whether any apparent benefits were truly due to the serum or simply the consequence of placebo response, natural skin variation, or other external factors.
Beiersdorf, the company behind Eucerin, attempted to justify the “up to five years younger” claim by contending it represented a genuine maximum result rather than a standard result. However, the ASA’s concerns extended beyond the main investigation. The watchdog highlighted that the serum had been assessed in a different geographical region to the United Kingdom, creating doubt about whether results would translate to British consumers. Additionally, three supporting items of evidence provided by Beiersdorf consisted entirely of unpublished research, whilst a fourth item—a peer-reviewed investigation on the main active component—did not even evaluate the serum itself, further undermining the evidence supporting the strong anti-ageing claims.
- Study was missing control group to verify genuine product effectiveness
- Participant self-reporting created reporting bias into results
- Testing carried out in alternative climate conditions than UK conditions
- Backing evidence largely not published and methodologically questionable
Regulatory Concerns and Flawed Methodology
Why the Study Did Not Meet Requirements
The ASA’s examination revealed critical shortcomings in how Beiersdorf executed and communicated its research. The absence of transparent recruitment information ensured the watchdog was unable to confirm whether participants were actually indicative of the wider consumer population or if sampling bias had skewed results towards desirable conclusions. Without knowing how volunteers were chosen, whether they had existing familiarity with skincare products, or if they held existing preferences for the brand, the reliability of their answers became deeply problematic. These research limitations are exactly what that oversight authorities examine closely when assessing assertions that could influence purchasing decisions.
Self-reporting by study participants introduced a substantial layer of subjective interpretation into the findings. Asking individuals to gauge how many years younger they appeared is fundamentally problematic, as perceptions of ageing are highly individual and influenced by mental processes, environmental lighting, and individual expectations. The ASA rightly questioned whether participants’ responses reflected genuine physical changes or merely their hopes and beliefs about the product’s efficacy. This distinction holds significant weight when a company seeks to market a £49 serum as “clinically proven”—a phrase implying rigorous, objective scientific validation rather than subjective personal impressions.
- No comparison cohort meant impossible to isolate the actual effects
- Recruitment process not revealed, introducing selection bias concerns
- Subjective self-assessment cannot constitute clinical proof of efficacy
- Different testing climate weakened applicability to UK consumers
- Backing data mostly undisclosed, preventing independent scientific scrutiny
Common Challenge with Beauty Advertising
The Eucerin serum ban is merely the latest in a pattern of misleading claims that has plagued the cosmetics advertising industry for years. Beauty companies have repeatedly pushed the limits of permissible marketing language, leveraging aspirational messaging and pseudo-scientific language to persuade consumers that products provide dramatic outcomes. Lianne Sykes, an marketing specialist in aesthetics who consults with firms on responsible marketing conduct, stresses that this problem is systemic rather than isolated. Companies often place emphasis on compelling marketing narratives over rigorous substantiation, relying on the presumption that consumers will not scrutinise claims too closely or that regulatory action will be slow.
The cosmetics market capitalises on inherent appetite for noticeable enhancements in appearance, establishing fertile ground for overstated claims. When firms use phrases like “clinically proven” without fulfilling the stringent standards that such language necessitates, they exploit the trust customers put in scientific terminology. The ASA’s conclusions suggest that Beiersdorf’s approach—offering unpublished research, carrying out studies in unsuitable climates, and using subjective self-assessment—exemplifies a concerning but not uncommon strategy. Without regular monitoring and improved disclosure from producers, consumers stay susceptible to marketing claims that favour revenue over honesty.
What People Should Ask About
Rather than accepting cosmetic claims uncritically, consumers should develop a more sceptical approach to assessing cosmetic advertising. Sykes recommends asking fundamental questions when making purchases, particularly when companies put forward assertions about visible results. Understanding the testing methods used, who takes part in studies, and what metrics are actually measured can uncover whether claims rest on solid evidence or marketing spin. Consumers must acknowledge that healthy skin typically results from regular routines and individual biology rather than putting faith in a single miracle product, no matter its price point or branding.
- How is skin condition systematically assessed and tracked over time?
- Were trials conducted on varied age ranges and skin types?
- Is the evidence published and independently verifiable by scientists?
- Does the test conditions align with actual conditions where people reside?
Beiersdorf’s Response and Future Implications
Beiersdorf, the German multinational corporation behind the Eucerin brand, has maintained that its products are underpinned by legitimate scientific research conducted in accordance with industry standards. The company defended its choice to state the claim as “up to” five years younger, contending this phrasing accurately reflected the true maximum outcome observed rather than a typical outcome. However, the ASA’s thorough examination of the methodology—including the lack of a control group, lack of transparency about participant recruitment, and reliance on subjective self-reporting—suggests that sector guidelines by themselves might not be adequate to protect consumers from false claims.
The ban signals a wider movement in regulatory enforcement against cosmetics advertising, though questions remain about whether individual instances result in systemic change. Beiersdorf confirmed that the billboard advertisement is no longer live in the UK, but the ruling raises important questions about how extensively comparable assertions persist across alternative offerings and marketing channels. If enforcement proceeds at this rate, companies could experience mounting pressure to commit resources to genuinely robust clinical evidence rather than depending on the ambiguity of unsubstantiated findings. For consumers, this case highlights the necessity of demanding transparency and questioning even long-standing brands.